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Leading researchers working on synthetic biology and its applications gathered at the
University of Edinburgh in May 2018 to discuss the latest challenges and opportunities
in the field. In addition to the potential socio-economic benefits of synthetic biology,
they also examined the ethics and security risks arising from the development of
these technologies. Speakers from industry, academia and not-for-profit organizations
presented their vision for the future of the field and provided guidance to funding and
regulatory bodies to ensure that synthetic biology research is carried out responsibly
and can realize its full potential. This report aims to capture the collective views and
recommendations that emerged from the discussions that took place. The meeting was
held under the Chatham House Rule (i.e., a private invite-only meeting where comments
can be freely used but not attributed) to promote open discussion; the findings and
quotes included in the report are therefore not attributed to individuals. The goal of
the meeting was to identify research priorities and bottlenecks. It also provided the
opportunity to discuss how best to manage risk and earn public acceptance of this
emerging and disruptive technology.
Keywords: synthetic biology, biosystem, future trends and developments, biodesign automation, responsible
research and innovation (RRI)
INTRODUCTION
Synthetic Biology offers innovative approaches for engineering new biological systems or re-
designing existing ones for useful purposes (see Figure 1). It has been described as a disruptive
technology at the heart of the so-called Bioeconomy, capable of delivering new solutions to global
healthcare, agriculture, manufacturing, and environmental challenges (Cameron et al., 2014; Bueso
and Tangney, 2017; French, 2019). However, despite successes in the production of some high
value chemicals and drugs, there is a perception that synthetic biology is still not yet delivering
on its promise.
Moreover, there are some concerns from governments that synthetic biology expands the pool
of agents of concern, which increases the need to develop detection, identification and monitoring
systems, and proactively build countermeasures against chemical and biological threats (Wang
and Zhang, 2019). The participation of representatives from various government organizations
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FIGURE 1 | Synthetic biology is developing into a biodesign platform where it will be possible to apply the “design-build-test-iterate (or deploy)” to predictably create
cells or organisms able to produce a wide variety of novel molecules, materials or even cells for multiple applications.
at this meeting is testament to their commitment to maintaining
an active dialogue with the synthetic biology community. In this
way, they aim to keep abreast of the changing nature of threats
and provide the best advice to government about investment in
science and technology and the introduction or amendment of
regulatory processes.
The cost of DNA sequencing and synthesis have decreased
dramatically (Carlson, 2014; Kosuri and Church, 2014) and we
have access to more genetic information and more powerful
genetic engineering capabilities than ever before. Critical
investments in infrastructure are bearing fruit and, as is
described below, synthetic biology is increasingly becoming, at
least part of, the solution to many of our present and future
needs in medicine, food and energy production, remediation,
manufacturing, and national security. So what is the potential
of synthetic biology and what challenges does it still face to
realize this?
ADVANCES IN SYNTHETIC BIOLOGY: THE
STATE OF PLAY
Small Molecules: Production on Demand a
Reality
Despite the lack of predictability in biology, and current
technical constraints that limit data collection and analyses, we
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can now produce small molecules on demand using synthetic
biology approaches.
Probably the most impressive examples come from the
Foundry at the Broad Institute of MIT and Harvard. When the
Defense Advanced Research Projects Agency (DARPA) put the
MIT-Broad Institute Foundry’s design capabilities to the test, its
researchers were able to deliver 6 out of 10 molecules of interest
to the US Department of Defense in 90 days. This “pressure test”
confirms the potential of synthetic biology to address shortages
of key compounds quickly (Casini et al., 2018).
Indeed, many labs can now design and construct relatively
complex gene networks capable of generating a wide variety of
“designer”molecules in a range of host cells; however, this is often
a slow iterative process of trial and error.
As yet, very few small molecules inmedicine aremanufactured
using a synthetic biology process; it remains very difficult to
engineer microbes to carry out processes that Nature did not
intend. This is to be expected: the performance of microbes
is “good enough” from an evolutionary perspective. Microbes
evolved to address the specific needs and challenges of their
natural environments not those of industrial fermenters and
bioreactors. Gene Transfer from one system to another may
sound easy but in practice is hard work and rarely generates
sufficient reward (i.e., increased yield) to justify the investment
made. The application of automation and artificial intelligence
(e.g., in designing and building plasmids) may help to reduce the
time and cost—and improve return on investment—in the future
(Zhang et al., 2018).
“Scale up is product specific – we need more synthetic biology in the
production process”
Plants make alternative production platforms. Improvements in
mining plant genomes and the development of effective transient
expression systems have enabled large-scale production of, for
example, vaccines in tobacco plants in just a few weeks (Dirisala
et al., 2017; Emmanuel et al., 2018). Directing the production
of synthetic biological materials to plant chloroplasts also shows
promise (Boehm and Bock, 2019).
The photosynthetic reducing power generated in plant
chloroplasts can be harnessed for the light-driven synthesis
of bioactive molecules such as dhurrin, which protects plants
against insects (Gnanasekaran et al., 2016).
However, underlying all these platforms is a knowledge gap in
our understanding in how nature works. This makes it very hard
to apply the design/build/test/learn cycles used in conventional
engineering to the production of synthetic biological materials
whatever the production platform (yeast, bacteria, plants, or
human cells) if the platform itself is not well-understood (Sauro
et al., 2006).
What we need now are instruments able to measure and
characterize outputs, assisted by progress in robotics and
automation, and the application of machine learning approaches
to analyse the data generated. This will help us to generate
more robust models of biological systems, so we can improve
experimental design for future engineering strategies.
“We can do ‘build’. ‘Test’ is the challenge when we want to learn
from the iterative design process”
Healthcare: Reimagining Medicine
Synthetic biology is driving significant advances in biomedicine,
which will lead to transformational improvements in healthcare.
Already, patients are benefiting from so-called CAR (for chimeric
antigen receptor) technology, which engineers the immune cells
(T-cells) of the patient to recognize and attack cancer cells (June
et al., 2018).
Genetically engineered viruses are being used to correct
defective genes in patients with inherited diseases such as Severe
Combined Immune Deficiency (SCID) or epidermolysis bullosa
(Dunbar et al., 2018).
The ability to reprogramme somatic cells from patients into
induced pluripotent stem cells is furthering our understanding of
their disease, reducing the use of animals in research, and paving
the way for the development of personalized medicines and cell
therapies. In principle at least, we could engineer a patient’s own
cells to multiply, differentiate into different cell types and even
self-assemble into new tissues, or even organs, to repair those
damaged through disease or injury (Davies and Cachat, 2016;
Satoshi et al., 2018).
Work on new vectors that are able to deliver large genetic
loads to target tissues is helping to produce more efficient
therapeutics and vaccines that will have fewer side effects and a
smaller risk of resistance. Furthermore, optimizing antibody or
vaccine production, or example, so that they are in an edible
format (e.g., plant based), could greatly reduce the cost and
increase the speed of vaccine production in an epidemic.
“We have the tools but need the creativity to make stuff that can’t
be made without synthetic biology”
In the next few years, genetically engineering pigs to be
virus resistant and have human-like immune profiles could
make xenotransplantation a clinical reality (Burkard et al.,
2018). Engineering the microbiome is expected to lead to the
development of synthetic probiotics (Dou and Bennett, 2018).
The synthetic biology initiative known as Human Genome
Project-write (HGP-write) has set its sights even higher, rallying
scientists to build entire human chromosomes (Boeke et al.,
2016). Concerns have been raised about the ethics of creating
“synthetic humans” and indeed the scientific and commercial
value of such a project. More recently, HGP-write champions
have proposed a more focused project to build a virus-resistant
chromosome, making at least 400,000 changes to the human
genome to remove DNA sequences that viruses use to hijack cells
and replicate (Dolgin, 2018).
One of the many exciting opportunities that synthetic biology
offers medicine is in the production of theranostic cell lines that
can sense a disease state and produce an appropriate therapeutic
response (Teixeira and Fussenegger, 2019). Several obstacles need
to be overcome to achieve this goal: first, to expand the range of
molecules that can be recognized by cellular “sensors” as inputs;
and second, to better understand the genetic control factors that
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regulate gene expression in space and time so we can engineer
better activator systems.
“At present we need pills because we can’t swallow a chemistry kit”
Metabolomics is shedding light on many disease biomarkers.
Because some biomarkers are shared between seemingly
unrelated diseases, an accurate diagnosis will require the
detection of multiple markers to provide a more unique “disease
fingerprint.” Work in whole cell and cell free systems to develop
sensors of multiple disease-specific biomarkers could assist in
earlier detection of disease and prognostic monitoring.
To expand the range of biologically detectable molecules,
it is possible to design metabolic pathways that transform
currently undetectable molecules of interest (e.g., hippuric acid,
the prostate cancer biomarker) into molecules for which sensors
already exist (in this case benzoic acid) (Libis et al., 2016).
Cybergenetics is an emerging field that is developing
experimental tools for the computer control of cellular processes
at the gene level in real time. Cybergenetic control can be
achieved by interfacing living cells with a digital computer that
switches on or off the embedded “genetic switch” using light
(optogenetics) or chemicals (Gabriele et al., 2018; Maysam et al.,
2019). Such systems could help to maintain cellular homeostasis
by monitoring the state of the body and triggering an appropriate
response upon the detection of dysregulation; for example, they
could trigger the release of insulin when blood glucose levels rise
as detected by a wireless diagnostic tool (Ye et al., 2011).
Advanced Materials: Inspired by Nature,
Improved by Synthetic Biology
Synthetic biology offers the opportunity to create responsive
and multifunctional materials (Le Feuvre and Scrutton, 2018).
The integration of biochemical components from living systems
with inorganic components can lead to new materials that are
able to sense the environment (or internal signals) and change
their properties. These features could be particularly useful for
improving protective clothing or building materials.
An issue when using microbes to produce composite
materials is regulating the assembly of these materials to achieve
specific desired properties. By understanding how microbes
communicate with each other, it is possible to make them
work better together and combine them with other production
systems so that the properties of materials can be tailored for
particular functions.
Interestingly, rather than modifying, or improving existing
protein-based materials, an alternative approach involves using
computational techniques to design completely novel proteins
that self-assemble into predicted shapes (Ljubeticˇ et al.,
2017). Such “programmable” proteins open up even further
opportunities for synthetic biology not only for materials science
but also for medicine and chemistry.
“The tools are there, we just don’t know what we want to make”
TACKLING THE CHALLENGES
Regardless of the research areas involved, there are some
common challenges for the community to address.
Design With the End in Mind
There was consensus that while the production of small
molecules using synthetically engineered cells at the bench is
becoming more tractable, these processes often do not translate
well into mass production. Scalability needs to be incorporated
into the initial design process by including features, for
example, that reduce toxicity of the molecule to the production
host or “chassis” and/or by introducing modifications that
favor its extraction. Careful consideration of the right chassis
could also greatly improve yields and significantly reduce cost
of production.
“Nature has developed its own ways to concentrate and solubilise
chemicals... we are not learning from this”
Expanding the Host Repertoire
The number of microbes that are currently in use for the
production of synthetic biological materials is only a tiny
fraction of the total diversity that exists in Nature; only ten
microbes are “domesticated” for industrial use. To identify
the most appropriate chassis, it is worth turning to nature to
identify species that have unique metabolic networks suited
to host particular types of chemical reactions. For example,
the soil bacterium Pseudomonas putida, which has adapted to
harsh environmental conditions, is ideally suited to host redox-
intensive reactions (Pablo and de Lorenzo, 2018). A treasure
trove of, as yet, unexplored natural products, with novel and
beneficial properties, exist in the plant kingdom. In addition,
as noted above, plants are naturally excellent production hosts
and it is now possible to “plug and play” combinations of
plant pathways to generate novel molecules (Sainsbury and
Lomonossoff, 2014; Evangelos and O’connor, 2016).
Developing a Universal Production System
To circumvent the problem of the impact of different host
chassis on synthetic gene circuits, researchers would benefit
from a universal synthetic expression system that permits the
testing of new constructs. This would aid in the identification
of optimal production platforms and decrease the need for
organism-specific technologies. Combining this technology with
DNA editing techniques, such as CRISPR/Cas9, will make the
establishment of host production platforms and the generation of
complex biosynthetic products easier and faster. One articulation
of this could be in cell-free formats, in which the essential cellular
machinery is reconstituted in vitro and used as a manufacturing
platform (Villarreal and Tan, 2017; Koch et al., 2018).
“We need to reduce the burden of synthetic networks on
endogenous circuits”
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Move to Cell-Free Environments
Cell-free environments, interfaced with semiconductors, offer a
powerful route for flexible and controllable production systems.
For example, nanoparticles made of semiconductor materials
or quantum dots can be used to enhance enzyme activity in
a cell free environment with a minimal set of ingredients.
Multistep enzymatic pathways can be tethered to nanoparticle
surfaces and, by avoiding the diffusion effect that takes place
in cells, reaction rates can be increased 100-fold (Wang
et al., 2017). This approach can be used to access non-
natural materials and circumvents the potential issue of
toxicity in cells (as well as the regulatory issues of genetically
modified cells).
Research on silicon chips containing immobilized genes and
cell lysates allows detailed examination of gene expression
in space and time. When the compartments in which
DNA-driven reactions take place are linked, with materials
flowing into and diffusing between the compartments, it is
possible to recreate oscillating protein expression patterns
and protein gradients akin to those observed in cells
(Karzbrun et al., 2014). Gene expression in these “artificial
cells” can be controlled with electrodes that prevent the
assembly of proteins by ribosomes. By standardizing outputs,
this strategy is improving the predictability of engineered
genetic circuits.
Systems Modeling, Standards, and
Metrology
Whatever the system being explored, a robust model of that
biological system is needed if predictable modifications of genetic
circuits are to be designed and implemented with any confidence.
To create such models, large sets of data arising from measuring
multiple parameters of cell behavior under different conditions
are essential (Fletcher et al., 2016).
There is great expectation that improvements in high-
throughput data measurement and collection systems will
generate exactly the large data sets needed. These can be analyzed
using artificial intelligence or a machine learning approach to
optimize the design of synthetic biological products and move
away from the inefficient trial and error process (Decoene et al.,
2018).
Finally, agreement on standards of design, assembly, data
transfer, data measurement and regulatory rules, as well as on the
language that is used, will help to improve the interdisciplinary
and international collaborations that are required to drive the
field forward. This is challenging for a community with such
diverse interests and perspectives, and where data sharing,
curating and quality control is not common practice.
However, without some form of agreed standards, many of the
products and processes of synthetic biology will not translate well
to industrial settings dependent on reproducible processes and
beholden to exacting regulatory requirements.
Typically, academic researchers are driven by a need to
understand the complexity of nature (and publish their work in
high impact journals). Standardization and scaling up production
are important, but have less of an academic pull than discovering
a new product. Access to funding, industrial partnerships, and
academic recognition are examples of potential incentives for
carrying out this type of research.
“Standards restrict flexibility but enable interoperability”
TACKLING RISK
Synthetic biology is an example of a dual-use technology: it
promises numerous beneficial applications, but it can also cause
harm. This has led to fears that it could, intentionally or
unintentionally, harm humans or damage the environment. For
example, there is huge value in our ability to engineer viruses
to be more effective and specific shuttles for gene therapies
of devastating inherited disorders; however, engineering viruses
may also lead to the creation of even more deadly pathogens by
those intent on harm.
“Synthetic biology should be regarded as an extension of earlier
developments and technologies”
Some would argue that synthetic biology poses an existential
risk and needs to be treated with extreme caution. However,
many new technological advances across the decades have met
similar concerns. The uncertainty and remote possibility of
such risks could hamper the development of useful technology.
Scientists, their host institutions and funding bodies should
(and indeed already do) consider whether the research planned
could be misused. Measures that reduce the likelihood of
misuse and its consequences should be implemented and clearly
communicated. The synthetic biology community needs to be
aware of, and respond to, these challenges by engaging in horizon
scanning exercises as well as open dialogue with regulatory bodies
and the media.
“Don’t avoid risk – manage it”
Being more open about risks, and how they are controlled,
provides an opportunity to shift discourse toward the benefits
of synthetic biology in addressing urgent global needs, such
as the production of biofuels, food security and more effective
medicines, and potentially improve public acceptance.
“The questions should not be ‘what’s the next big thing for synthetic
biology’ but ‘where is the greatest unmet need’.”
Despite the efforts by individual countries to establish synthetic
biology research roadmaps, broader, international agreement on
common standards (and red lines) across the field may help
establish trust and to advance the best pre-competitive research
into useful applications.
Meeting participants highlighted the importance of training
in responsible research conduct and ethics. Given students’ future
role as science ambassadors and influencers, their training should
not only convey skills and knowledge but also awareness and
critical thinking about the prospects and potential for dual use of
synthetic biology. All researchers must remain vigilant regardless
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of the many pressures and distractions of running a successful
research lab; they may not have specialist training in identifying
the risks of misuse but they are the people best placed to maintain
informed oversight of risks.
One example of current synthetic biology research with
potential dual use is gene drive technology, which can be
used to propagate a particular suite of genes throughout
a population. The benefits of using gene drive technology
include the eradication of disease-carrying insect populations
and the elimination of invading pest species but it has raised
concerns about the unintended ecological impacts of reducing or
eliminating a population (Callaway, 2018; Collins, 2018).
Similar release concerns surround research that is harnessing
the ability of pathogens to target particular tissues in the
body or particular chemicals in the environment, which
could greatly aid efforts to deliver targeted therapies or
clean-up contaminated sites. To date, such large-scale release
for environmental bioremediation interventions has not
been possible.
“We need to mind the gap between R&D scale up and
communications . . . . One bad blog can kill a commercial product”
There was consensus that the need for regulation over this
community remains important. Regulation needs to keep up to
speed with the emerging technologies and should focus on the
product rather than the process used to create it (Tait et al.,
2017). Unsuitable regulatory frameworks (as well as unfavorable
public perception) could discourage private sector investment in
synthetic biology.
Open and balanced two-way communication between
researchers, funders, companies and governments and the public
will be vital. Consumers and activists may have no interest in the
difference between making a chemical (e.g., a flavor or fragrance)
synthetically and one made using genetically modified bacteria
but they may instinctively distrust the latter.
CONCLUSIONS AND
RECOMMENDATIONS
The short talks presented at this 2-day meeting suggest that
synthetic biology is at the cusp of many major breakthroughs and
that it is perhaps timely to re-define the meaning of “success” in
synthetic biology.
There are many hurdles to overcome but the potential for
synthetic biology to deliver solutions to many global challenges—
improving healthcare, limiting environmental damage, and
creating a wide variety of more sustainable processes—is great.
Meeting participants suggested that as a community they
should support the measures listed below to help synthetic
biology move beyond the proof-of-concept stage and to ensure
that potential risks are minimized and dialog with the public can
be optimized.
• Larger and longer investment in better big data management
and processing (Artificial Intelligence and Machine Learning)
systems, and in fundamental research on biosystems
modeling, chassis development, and genome mining.
• Support standardization initiatives; while arguably not
attractive academically, the community needs to agree and
support efforts toward creating interoperability around
biosystem modeling, and standards around DNA design (if
not DNA bioparts). Without some degree of “standardization”
the ability to pool data and models, essential for improving
accuracy and reproducibility, will be challenging.
• The creation and funding (ideally internationally) of a “Grand
Challenge,” such as the development of generic sensors or the
creation of protein-based electronic components, could help
focus the community toward a target goal.
• Improve the assessment, communication, and management of
risk and harm among all audiences.
• Ensure that early career researchers are trained in responsible
research conduct and ethics as well as being cognizant
of existing rules and regulations around GM (regionally
dependent) and the issue of misuse and harm.
• Coordinate the efforts of academia, government and industry
through focused meetings that foster interdisciplinary
collaborations around shared objectives.
• Improve platforms for knowledge sharing and recognize the
value of failures.
The workshop highlighted just how much more we have to
learn from Nature itself. Synthetic biology is giving us insights
of the criteria and processes that underpin all living systems; in
turn, we can take this insight and design and use it to build
a “better biology.” However, we need to take the public with
us on this journey, create meaningful and considered dialogue
about the work we may do and the impact it might have on
our world.
AUTHOR’S NOTE
The meeting was hosted by the UK Center for Mammalian
Synthetic Biology (the Center), based at the University of
Edinburgh. The Center is building expertise in cell engineering
tool generation, whole-cell modeling, computer-assisted design
and construction of DNA and high-throughput phenotyping
to enable synthetic biology for medicine and healthcare. The
Centre’s research will not only advance basic understanding of
mammalian biology and pathology but also generate products
and services for near-term commercial exploitation by the
pharmaceutical and drug testing industries, such as diagnostics,
novel therapeutics, protein-based drugs, and regenerative
medicines. The Center is funded through the Research Council’s
UK “Synthetic Biology for Growth” programme and by
the Biological and Biotechnology Sciences Research Council
(BBSRC), the Engineering and Physical Sciences Research
Council and the Medical Research Council.
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